NCT04398030View on ClinicalTrials.gov

"Pharmacokinetics (PK)/ Pharmacodynamics (PD) of an Extended Wear Infusion Set for Continuous Subcutaneous Insulin Infusion (CSII) in Type 1 Diabetes Mellitus (T1DM) Patients (PEXIS)"

NACompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

July 17, 2020

Primary Completion Date

April 22, 2021

Study Completion Date

April 22, 2021

Conditions
Diabetes Mellitus, Type 1Type 1 Diabetes
Interventions
DEVICE

coil-reinforced soft polymer indwelling cannula

Insulin infusion set will be used for up to 7 days of continuous use or until failure

DEVICE

soft Teflon indwelling catheter

Insulin infusion set will be used for up to 7 days of continuous use or until failure

Trial Locations (1)

92025

AMCR Institute, Escondido

Sponsors
All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

collaborator

AMCR Institute

OTHER

collaborator

Integrated Medical Development

INDUSTRY

lead

Capillary Biomedical, Inc.

INDUSTRY